COX Nicox SA

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Press Release
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
  • Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan
  • Triggers a €2 million milestone payment to Nicox
August 5, 2025 – release at 7:30 am CET

Sophia Antipolis, France



Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 (also known as K-911) in Japan for the treatment of ocular hypertension, triggering a €2 million milestone payment to Nicox. Only one Phase 3 confirmatory clinical trial in Japanese patients, which will start shortly, plus this safety trial, is required for submission for marketing approval of NCX 470 in Japan. Kowa is responsible for financing and managing the trials under the license agreement with Nicox.



Thanks to our continuing collaborative efforts after Kowa received approval to initiate this trial, we are very pleased to announce that the first patient has been enrolled. The Phase 3 trials in Japan are being managed and financed by Kowa, and only one confirmatory Phase 3 trial is expected to be needed to make a submission for marketing approval of NCX 470 in Japan.” said Doug Hubatsch, EVP Scientific Officer of Nicox.



The trial announced today is a safety trial and is detailed here: . The 500 patient confirmatory trial is expected to start shortly and is detailed here: .







About NCX 470







NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development programs in the U.S., China and Japan for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the Phase 3 clinical trials, have been extensively and are available on our website. All patients have completed the second Phase 3 clinical trial, Denali, and topline results are expected mid-August to mid-September 2025. Mont Blanc and Denali have been designed to fulfil the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China. A separate Phase 3 clinical program is underway to support Japanese approval. NCX 470 is exclusively licensed to Ocumension Therapeutics in China, Korea and Southeast Asia and to Kowa in the rest of the world.
About Nicox
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa elsewhere.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos.  Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories.  Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.  



Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.



For more information
Analyst coverage








H.C. Wainwright & Co Yi Chen New York, U.S.




The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts 
Nicox

Gavin Spencer

Chief Executive Officer

T +33 (0)4 97 24 53 00





 
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.



Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website ().



Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.
Nicox S.A.

Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France

T +33 (0)4 97 24 53 00

Attachment



EN
05/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety cl...

 PRESS RELEASE

Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique...

Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase 3 pour NCX 470 au Japon Communiqué de presseNicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase 3 pour NCX 470 au Japon Kowa, le partenaire exclusif de Nicox au Japon, a initié un essai clinique de sécurité de Phase 3 sur NCX 470 pour le traitement de l’hypertension oculaire au Japon  Le lancement de cet essai déclenche un paiement d’étape de 2 millions d’euros pour Nicox 5 août 2025 – publication à 7H30 Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALC...

 PRESS RELEASE

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclu...

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 millionTiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa wil...

 PRESS RELEASE

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 mi...

Nicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés Communiqué de presseNicox et Kowa signent un accord clé pouvant atteindre jusqu’à 191,5 millions d’euros pour les droits exclusifs du traitement du glaucome NCX 470 aux Etats-Unis et dans l’ensemble des territoires non-licenciés Un paiement initial de 7,5 millions d’euros, avec des paiements d’étapes de développement et de commercialisation pouvant atteindre un total de 191,5 millions...

 PRESS RELEASE

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clin...

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470, its lead comp...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch